Imvax Inc. Raises $112 Million in Series C Financing
Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research into additional solid tumor indications and build out of the operational capabilities
PHILADELPHIA, JULY 16, 2020 – Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being studied in patients with glioblastoma multiforme (GBM), and whose proprietary technology has the potential to advance care for patients with serious, unmet medical needs in other solid tumor cancers, today announced the completion of a $112 million Series C financing. The round was led by existing investor HP WILD Holding AG, with significant participation from other major shareholders – Ziff Capital Partners, Magnetar Capital, and TLP Investment Partners. This round also includes participation from a new institutional investor – Invus.